Xtant Medical Holdings, Inc.
XTNT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for XTNT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · XTNT
Xtant Medical Holdings, Inc. is a medical technology company focused on surgical solutions for musculoskeletal disorders, offering orthobiologics and spine hardware systems primarily in the U.S. market.
Key risk: Revenue covenant compliance
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for Xtant Medical Holdings, Inc..
Xtant Medical Holdings, Inc. is a medical technology company focused on surgical solutions for musculoskeletal disorders, offering orthobiologics and spine hardware systems primarily in the U.S. market.
- Cash and cash equivalents of $10.2M as of June 30, 2026 [sec_mda · as of 2026-08-11].
- Total revenue of $23.0M and net loss of -$9.4M for the six months ended June 30, 2026 [latest reported financials].
- Shareholders' equity of $48.5M and total debt of $11.0M as of June 30, 2026 [latest reported financials].
- Products are sold through independent agents and stocking distributors in the U.S., with international distribution in Europe, Canada, Mexico, South America, and certain Pacific region countries [sec_mda · as of 2026-03-31].
- The company has biologics contracts with major GPOs and extensive access to IDNs across the U.S. [sec_mda · as of 2026-03-31].
What works
- The company has a diversified product portfolio including orthobiologics and spine hardware systems, with established distribution channels in the U.S. and internationally [sec_mda · as of 2026-03-31].
- Management believes existing cash and anticipated operating cash flows will be sufficient to meet cash requirements, supported by recent credit agreement amendments [sec_mda · as of 2026-08-11].
- The company has secured biologics contracts with major GPOs and has extensive access to IDNs, providing a strong market presence [sec_mda · as of 2026-03-31].
What to weigh
- The company reported a net loss of -$9.4M for the six months ended June 30, 2026, indicating ongoing unprofitability [latest reported financials].
- Cash and cash equivalents decreased from $17.3M at December 31, 2025 to $10.2M at June 30, 2026, reflecting cash burn [sec_mda · as of 2026-08-11].
- The company was not in compliance with the minimum net revenue covenant for the quarter ended June 30, 2026, prior to a recent amendment [sec_mda · as of 2026-08-11].
- There is no assurance that the company will not need or seek additional capital before May 2027 to fund operations [sec_mda · as of 2026-05-13].
From the filings
Quoted directly from source documents.
Cash position as of June 30, 2026
“We believe that our $10.2 million of cash and cash equivalents as of June 30, 2026”
SEC MD&A · August 11, 2026
Revenue covenant non-compliance risk
“we were not required to comply with the minimum net revenue covenant for the quarter ended June 30, 2026. Under the covenant terms in effect prior to the Amendment No. 5s, we would not have been in compliance with the minimum net revenue requirement for that quarter.”
SEC MD&A · August 11, 2026
Sales channel and market access
“We have an extensive sales channel of independent commissioned agents and stocking distributors in the United States representing some or all of our products. We also maintain a national accounts program to enable our agents to gain access to integrated delivery network hospitals and through group purchasing organizations.”
SEC MD&A · March 31, 2026
Cash runway uncertainty
“we may require or seek additional capital to fund our future operations and business strategy prior to May 2027. Accordingly, there is no assurance that we will not need or seek additional financing prior to such time.”
SEC MD&A · May 13, 2026
Risks & what to watch (4)›
Key risks
- Revenue covenant compliance — Company was not in compliance with minimum net revenue covenant for Q2 2026 prior to amendment [sec_mda · as of 2026-08-11]
- Cash burn and liquidity — Cash decreased from $17.3M to $10.2M in six months; may need additional capital [sec_mda · as of 2026-08-11]
- Ongoing net losses — Net loss of -$9.4M for six months ended June 30, 2026 [latest reported financials]
- Debt covenant risk — Credit agreements include minimum net revenue covenant; future compliance uncertain [sec_mda · as of 2026-08-11]
What to watch
- Future compliance with minimum net revenue covenants under the credit agreements [sec_mda · as of 2026-08-11].
- Cash burn rate and potential need for additional financing before May 2027 [sec_mda · as of 2026-05-13].
- Progress on key growth initiatives including strategic acquisitions and technology licensing [sec_mda · as of 2025-11-10].
- Revenue trends and ability to achieve profitability [latest reported financials].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Xtant Medical Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Xtant Medical Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
10.9 months
D/E 0.99 · 0% dilution
No tracked pipeline phase
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
31
Total value held
$4.4M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 4,029,206 | $2.2M |
| renaissance technologies llc | 987,410 | $551K |
| geode capital management, llc | 529,214 | $295K |
| crescent grove advisors, llc | 412,024 | $230K |
| nano cap new millennium growth fund l p | 350,000 | $195K |
| vanguard fiduciary trust co | 257,988 | $144K |
| bridgeway capital management, llc | 164,100 | $92K |
| citadel advisors llc | 161,011 | $90K |
| millennium management llc | 132,354 | $74K |
| blackrock, inc. | 115,782 | $65K |
Showing top 10 of 31 institutional holders of Xtant Medical Holdings, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 0.1%
- Days to cover
- 0.3
- Shares short
- 39,674
- Daily short volume (Jun 29, 2026)
- 39.6%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
XTNT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Xtant Medical Holdings, Inc.?
Xtant Medical Holdings, Inc. is a medical technology company focused on surgical solutions for musculoskeletal disorders, offering orthobiologics and spine hardware systems primarily in the U.S. market.
Who is the CEO of Xtant Medical Holdings, Inc.?
Mr. Sean E. Browne is the chief executive officer of Xtant Medical Holdings, Inc. (XTNT).
Where is Xtant Medical Holdings, Inc. headquartered?
Xtant Medical Holdings, Inc. (XTNT) is headquartered in Belgrade, MT, United States.
What therapeutic areas does Xtant Medical Holdings, Inc. focus on?
Xtant Medical Holdings, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.